Joel Greenblatt's IDXX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 48,643 shares of IDEXX Laboratories, Inc. (IDXX) worth $31.08 M, representing 0.14% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in IDXX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2014, adding 305,010 shares. Largest reduction occurred in Q3 2017, reducing 308,437 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's IDEXX Laboratories (IDXX) Holding Value Over Time
Track share changes against reported price movement
Quarterly IDEXX Laboratories (IDXX) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +7,676 | Add 0.00% | 7,674 | $44.83 |
| Q3 2013 | -1,768 | Reduce 23.04% | 5,906 | $49.78 |
| Q4 2013 | -238 | Reduce 4.03% | 5,668 | $53.11 |
| Q1 2014 | -32 | Reduce 0.56% | 5,636 | $60.68 |
| Q2 2014 | -5,636 | Sold Out | 5,636 | $0.00 |
| Q3 2014 | +310,646 | New Buy | 310,646 | $58.92 |
| Q4 2014 | -310,646 | Sold Out | 310,646 | $0.00 |
| Q3 2017 | +2,209 | New Buy | 2,209 | $155.27 |
| Q4 2017 | +2,411 | Add 109.14% | 4,620 | $156.28 |
| Q1 2018 | -4,620 | Sold Out | 4,620 | $0.00 |
| Q4 2018 | +5,413 | New Buy | 5,413 | $186.03 |
| Q1 2019 | -5,413 | Sold Out | 5,413 | $0.00 |
| Q4 2019 | +7,865 | New Buy | 7,865 | $261.16 |
| Q1 2020 | -7,865 | Sold Out | 7,865 | $0.00 |
| Q3 2020 | +6,661 | New Buy | 6,661 | $393.18 |
| Q4 2020 | -485 | Reduce 7.28% | 6,176 | $499.84 |
| Q1 2021 | -44 | Reduce 0.71% | 6,132 | $489.24 |
| Q2 2021 | -489 | Reduce 7.97% | 5,643 | $631.58 |
| Q3 2021 | +772 | Add 13.68% | 6,415 | $621.82 |
| Q4 2021 | -4,338 | Reduce 67.62% | 2,077 | $658.64 |
| Q1 2022 | +1,807 | Add 87.00% | 3,884 | $547.12 |
| Q2 2022 | +8,926 | Add 229.81% | 12,810 | $350.74 |
| Q3 2022 | +51 | Add 0.40% | 12,861 | $325.79 |
| Q4 2022 | -1,324 | Reduce 10.29% | 11,537 | $407.96 |
| Q1 2023 | -663 | Reduce 5.75% | 10,874 | $500.08 |
| Q2 2023 | -1,188 | Reduce 10.93% | 9,686 | $502.23 |
| Q3 2023 | +7,741 | Add 79.92% | 17,427 | $437.27 |
| Q4 2023 | -8,799 | Reduce 50.49% | 8,628 | $555.05 |
| Q1 2024 | +9,914 | Add 114.90% | 18,542 | $539.93 |
| Q2 2024 | -2,882 | Reduce 15.54% | 15,660 | $487.20 |
| Q3 2024 | +3,702 | Add 23.64% | 19,362 | $505.22 |
| Q4 2024 | -5,600 | Reduce 28.92% | 13,762 | $413.44 |
| Q1 2025 | +6,687 | Add 48.59% | 20,449 | $419.95 |
| Q2 2025 | +14,208 | Add 69.48% | 34,657 | $536.34 |
| Q3 2025 | +13,986 | Add 40.36% | 48,643 | $638.89 |
Joel Greenblatt's IDEXX Laboratories Investment FAQs
Joel Greenblatt first purchased IDEXX Laboratories, Inc. (IDXX) in Q2 2013, acquiring 7,674 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held IDEXX Laboratories, Inc. (IDXX) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to IDEXX Laboratories, Inc. (IDXX) was in Q3 2014, adding 310,646 shares worth $18.3 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 48,643 shares of IDEXX Laboratories, Inc. (IDXX), valued at approximately $31.08 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, IDEXX Laboratories, Inc. (IDXX) represents approximately 0.14% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in IDEXX Laboratories, Inc. (IDXX) was 310,646 shares, as reported at the end of Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.